Eliquis to face generic competition in late 2026? Bristol Myers Squibb (BMS) and Pfizer’s oral blood thinner – Eliquis® (Apixaban) was approved in the United
Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an IIT Bombay spin-off, backed by Hyderabad-based leading pharmaceutical and biotechnology multinational company (Laurus Labs) received the CDSCO approval
An Usher of Immunology Biosimilars in the Next 5 Years? Biosimilars are biologic medicines that are highly similar to existing licensed biologic products with no
A Detailed Analysis of Patent Term Extensions Expiring in the U.S. between 2023-2028 A drug manufacturer can enjoy monopoly in the market till 20 years
Novo Nordisk’s RivflozaTM gets the U.S. FDA approval for treatment of primary hyperoxaluria type 1 (PH1) On 29th September, Novo Nordisk obtained approval from the U.S.
SPC manufacturing waiver to be amended in 2024? Pharmaceutical companies in the European Union (EU) are entitled to a sui generis form of protection for their approved
